HLS Therapeutics Inc.

HLS.TOTSXHealthcare● Active

$4.41

$-0.06(-1.34%)

Market Cap$137917017

P/E Ratio—

52W High$5.765

52W Low$0.001

Avg Volume7K

Open$4.40

Beta0.85

Free Cash Flow Financials Revenue

HLS Therapeutics Inc. (HLS.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

HLS.TO · free cash flow · updated Jun 9, 2026

Core FCF metrics

HLS.TO · FCF · TTM · margin & CAGR

Free cash flow was $15.8M for FY2025 (fiscal year ending 2025-12-31), up 97.9% year-over-year The FCF margin was 28.0%.

FY2025 Free Cash Flow$15.8M▲ +97.9% YoY

Trailing 12M (TTM)$18.4Mtrailing 4 quarters sum

FCF Margin28.0%$15.8M ÷ revenue

3-Year CAGR+32.5%FY2022 → FY2025

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

HLS.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$16.0M(0M)$15.8M▲ +97.9%28.0%

FY2024$8.0M(0M)$8.0M▼ 48.8%14.1%

FY2023$15.8M(0M)$15.6M▲ +129.6%24.7%

FY2022$16.9M(10M)$6.8M▼ 43.0%11.1%

FY2021$16.4M(5M)$11.9M▲ +133.7%19.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

HLS.TO · P/FCF · FCF yield · FCF per share

HLS Therapeutics Inc. (HLS.TO) trades at a FCF yield of 18.68% and a price-to-free-cash-flow ratio of 7.6x. FCF per share stands at $0.58, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

18.68%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.58

TTM FCF ÷ Shares Outstanding

Price / FCF

x7.6

Share Price ÷ FCF per Share

EV / FCF (TTM)

x7.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

HLS.TO · cash flow statement · operating / investing / financing

For FY2025, HLS Therapeutics Inc. generated $16.0M in operating cash flow and spent 0M in capital expenditures, yielding $15.8M in free cash flow.

Operating Activities

+$16.0M

Cash from core business operations

2025-12-31

Investing Activities

−$1.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$20.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($16.0M) − |CapEx| (0M) = FCF ($15.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

HLS.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

HLS Therapeutics Inc.YOU

HLS.TO

$15.8M+97.9%28.0%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

HLS Therapeutics Inc. (HLS.TO) reported free cash flow of $15.8M for FY2025 (fiscal year ending 2025-12-31), up 97.9% year-over-year. The FCF margin was 28.0%.

Based on available data, HLS Therapeutics Inc. has maintained positive free cash flow for at least 12 fiscal year(s). FCF peaked at $32.0M in FY2018.

HLS Therapeutics Inc.'s FCF yield is 18.68% and price-to-FCF ratio is 7.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

HLS.TO free cash flow · 8 questions

HLS Therapeutics Inc. free cash flow was $15.8M for FY2025, up 97.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $18.4M.

HLS.TO free cash flowHLS.TO FCFHLS.TO FCF 2025HLS.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · HLS Therapeutics Inc. · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026